{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:57:53Z","timestamp":1778003873224,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ymgmr.2022.100946","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:07:00Z","timestamp":1671062820000},"page":"100946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Idiosyncratic drug-induced liver injury caused by givosiran in a patient with acute intermittent porphyria"],"prefix":"10.1016","volume":"34","author":[{"given":"Christopher D.","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Faust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert L.","family":"Bonkovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 6","key":"10.1016\/j.ymgmr.2022.100946_bb0005","article-title":"Drug-induced liver injury","volume":"16","author":"Katarey","year":"2016","journal-title":"Clin. Med."},{"issue":"20","key":"10.1016\/j.ymgmr.2022.100946_bb0010","doi-asserted-by":"crossref","first-page":"11397","DOI":"10.1021\/acs.jmedchem.0c00524","article-title":"Drug induced liver injury (DILI). Mechanisms and medicinal chemistry avoidance\/mitigation strategies","volume":"63","author":"Norman","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ymgmr.2022.100946_bb0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgmr.2022.100946_bb0020","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3389\/fphar.2019.00853","article-title":"Roussel Uclaf causality assessment method for drug-induced liver injury: present and future","volume":"10","author":"Danan","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.ymgmr.2022.100946_bb0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/hep.32327","article-title":"A revised electronic version of RUCAM for the diagnosis of DILI","volume":"76","author":"Hayashi","year":"2022","journal-title":"Hepatology."},{"issue":"1","key":"10.1016\/j.ymgmr.2022.100946_bb0030","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/liv.15090","article-title":"Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study","volume":"42","author":"Ventura","year":"2022","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.ymgmr.2022.100946_bb0035","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.pediatrneurol.2014.04.005","article-title":"Severe 5,10-methylenetetrahydrofolate reductase deficiency and two MTHFR variants in an adolescent with progressive myoclonic epilepsy","volume":"51","author":"D\u2019Aco","year":"2014","journal-title":"Pediatr. Neurol."},{"issue":"4","key":"10.1016\/j.ymgmr.2022.100946_bb0040","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/jimd.12411","article-title":"Acute intermittent porphyria, givosiran, and homocysteine","volume":"44","author":"Fontanellas","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"issue":"7","key":"10.1016\/j.ymgmr.2022.100946_bb0045","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00277-021-04547-3","article-title":"Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?","volume":"100","author":"Petrides","year":"2021","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.ymgmr.2022.100946_bb0050","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/jimd.12391","article-title":"Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran","volume":"44","author":"To-Figueras J","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.ymgmr.2022.100946_bb0055","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ymgme.2022.01.002","article-title":"Givosiran in acute intermittent porphyria: a personalized medicine approach","volume":"135","author":"Poli","year":"2022","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgmr.2022.100946_bb0060","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1002\/hep.31538","article-title":"HLA-B*35:01 and green tea-induced liver injury","volume":"73","author":"Hoofnagle","year":"2021","journal-title":"Hepatology."},{"issue":"4","key":"10.1016\/j.ymgmr.2022.100946_bb0065","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jhep.2021.12.013","article-title":"Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study","volume":"76","author":"Chalasani","year":"2022","journal-title":"J. Hepatol."},{"issue":"24","key":"10.1016\/j.ymgmr.2022.100946_bb0070","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ymgmr.2022.100946_bb0075","doi-asserted-by":"crossref","first-page":"205","DOI":"10.5582\/irdr.2020.03089","article-title":"Therapeutic strategies for acute intermittent porphyria","volume":"9","author":"Zhao","year":"2020","journal-title":"Intractable Rare Dis. Res."},{"issue":"6","key":"10.1016\/j.ymgmr.2022.100946_bb0080","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa1807838","article-title":"Phase 1 trial of an RNA interference therapy for acute intermittent porphyria","volume":"380","author":"Sardh","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ymgmr.2022.100946_bb0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/23808993.2021.1838275","article-title":"Givosiran, a novel treatment for acute hepatic porphyrias","volume":"6","author":"Thapar","year":"2021","journal-title":"Expert Rev. Precis. Med. Drug Dev."},{"issue":"1","key":"10.1016\/j.ymgmr.2022.100946_bb0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1358\/dot.2021.57.1.3230207","article-title":"Givosiran to treat acute porphyria","volume":"57","author":"Honor","year":"2021","journal-title":"Drugs Today (Barc.)"},{"key":"10.1016\/j.ymgmr.2022.100946_bb0095","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.2147\/DDDT.S281631","article-title":"Spotlight on givosiran as a treatment option for adults with acute hepatic porphyria: design, development, and place in therapy","volume":"16","author":"Majeed","year":"2022","journal-title":"Drug Des. Devel. Ther."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426922001069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426922001069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:52:30Z","timestamp":1762001550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426922001069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":19,"alternative-id":["S2214426922001069"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100946","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Idiosyncratic drug-induced liver injury caused by givosiran in a patient with acute intermittent porphyria","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100946"}}